Author

Chang-Ki Min

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

We report the results from a Phase 1 study (NCT04557150) evaluating subcutaneous (SC) forimtamig, a novel GPRC5DxCD3 bispecific antibody with a 2:1 configuration, in relapsed/refractory multiple myeloma (RRMM). After dose-escalation, backfilling at optimized target doses in combination with weekly (step-up: Cycle [C] 1...

Anna Caroline Hasselbalch, Simon J. Harrison, Salomon Manier et al. · Blood Advances · 0 citations

Open access Sep 2026

Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study

Background Blinatumomab, a bispecific T-cell engager, mediates cytotoxicity through CD3+ T-cell activation and has shown efficacy in relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although T-cell expansion correlates with favorable outcomes, routine immunophenotyping is impractica...

Seonghan Lee, Daehun Kwag, G. Min et al. · Therapeutic Advances in Hema... · 0 citations

Open access Sep 2026

Redefining the role of second transplantation in adult ALL with post-transplant relapse in the modern era of immuno-targeted therapies

To the Editor: Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains one of the most challenging events in adult acute lymphoblastic leukemia (ALL) and a leading cause of treatment failure [1, 2]. Second allo-HCT has historically been regarded as the only potentially curative option for patient...

Jaehyun Ahn, Daehun Kwag, G. Min et al. · Blood Cancer Journal · 0 citations